AJT Highlights podcast logo

New AJT Highlights episode now available!
#transplantation #TransplantTwitter #transplant

New global study of 2,600 living liver donors!
Robotic hepatectomy outperformed open & laparoscopic surgery — showing:
🩸 Less blood loss
💊 Lower pain
🏥 Shorter hospital stays
⚕️ Fewer complications. #TXPforAll #LiverTransplantation #TransplantTwitter
tinyurl.com/2tuxzfaz

Kidney Delayed Graft Function in Simultaneous... : Transplantation Direct to those without K-DGF among all adult SPK recipients transplanted at our center between January 2000 and December 2022 who had >2 wk of pancreas graft survival. Outcomes of interest included common posttransplant infections, including urinary tract infection (UTI), pneumonia, cytomegalovirus, BK, surgical wound infection, infected intra-abdominal fluid collection, graft rejection, and death-censored graft failure (DCGF) within the first year of transplant. We also looked for the need for early laparotomy within 90 d. Results. Seven hundred sixty-five SPK recipients were included, of whom 85 (11.1%) developed K-DGF. In Cox regression analysis, after adjustment for multiple key variables, K-DGF was associated/related with increased risk for UTI (adjusted hazard ratio [aHR], 1.76; 95% confidence interval [CI], 1.06-0.94; P = 0.03), infected intra-abdominal fluid collection (aHR, 2.14; 95% CI, 1.13-4.04; P = 0.02), and need for relaparotomy within 90 d (aHR, 2.07; 95% CI, 1.27-3.37; P = 0.003). K-DGF was also associated with increased risk for pancreas DCGF (aHR, 4.88; 95% CI, 1.90-12.51; P < 0.001). K-DGF was not associated with risk for other common infections of interest or graft rejection. Conclusions. K-DGF among SPK recipients is associated with an increased risk of UTI, infected intra-abdominal fluid collection, and the need for early relaparotomy, along with pancreas DCGF. Close monitoring and appropriate management are warranted in this higher-risk patient population....

Study on SPK transplant outcomes! Kidney delayed graft function (K-DGF) is linked to higher risks of UTI, intra-abdominal infections, early relaparotomy, and pancreas graft failure. Close post-op monitoring is key. @UWMadison #TXPforALL #TransplantTwitter tinyurl.com/ctsaezu7

The Efficacy of Ferroptosis Inhibition on... : Transplantation eview and meta-analysis summarizes the effects of pharmacological ferroptosis inhibition in abdominal organs in the setting of IRI. PubMed, Embase, Web of Science and Cochrane were searched for concepts “ferroptosis” and “IRI” in August 2023. To allow for meta-analyses, inhibitors were divided into different intervention pathways: (I) lipophilic radical scavengers, (II) iron chelators, (III) antioxidants, (IV) lipid metabolism inhibitors, (V) combination treatments, and (VI) others. When available, organ function and injury effect sizes were extracted and used for random-effects meta-analyses. In total 79 articles were included, describing 59 unique inhibitors in kidney, liver, and intestinal IRI. No studies in pancreas were found. Overall bias and study quality was unclear and average to low, respectively. Apart from 1 clinical study, all inhibitors were tested in preclinical settings. The vast majority of the studies showed ferroptosis inhibition to be protective against IRI under various treatment conditions. In liver and kidney IRI, meta-analyses on standardized effect sizes from 43 articles showed a combined protective effect against IRI compared with a nontreated controls for all analyzed intervention pathways. In conclusion, ferroptosis inhibition protects against abdominal IRI in preclinical research. Important questions regarding optimal intervention pathway, bioavailability, optimal dosage, side effects etc. should be addressed before clinical introduction....

A must-read review by Devos et al. highlighting the latest advances on how targeting ferroptosis may improve outcomes in ischemia-reperfusion injury. #TXPforALL #immunology #TransplantTwitter tinyurl.com/m9jr69a2

🚀 Powerful insights from today’s Social Media session at #WTC2025! About the future of transplant communication. 💬🧬📱 #TransplantTwitter @ttsorg.bsky.social @astinfo.bsky.social

🚨 LICOP at #WTC2025 🚨

Ami Patel is presenting an oral:
"Single-cell transcriptomic and proteomic landscape of cardiac allograft vasculopathy"
🗓 8/5 Tue ⏰ 14:00 📍 Room 9
Next-gen profiling of CAV offers insights for prevention and treatment.
#TransplantTwitter @astinfo.bsky.social

PTLD significantly reduces survival in high-risk EBV D+R– #KidneyTransplant recipients. Preventive strategies like rituximab may be cost-effective if highly effective & affordable. #TransplantTwitter #TXPforALL #OpenAccess tinyurl.com/y9xwxkjz

🚨Webinar Tomorrow 🚨

👉Advancing Best Practices: Position Statement on Neurocognitive and Physical Activity

📅 Tuesday, April 29 @ 12 pm (ET)

💬 Jemma Mears, Stephanie So, Catherine Patterson

Join here 🔗 tinyurl.com/33n9x84d

#transplanttwitter #medtwitter #transplantation

Glienke et al. demonstrate that the use of mDJ stents in kidney transplantation is a safe alternative associated with comparable pain during removal after #kidneytransplantation. #OpenAccess #TransplantTwitter #TXPforAll tinyurl.com/2ed4r6ah

Registration is now open for '#KidneyTransplant Updates 2025' - a virtual conference on Friday, April 4, 2025 with 7.0 ACCME credits.
www.eventleaf.com/e/KidneyTran...

#TransplantTwitter #NephTwitter #Transplant #KidneyTwitter #KidneyDisease #Kidney